title: Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months.
authors.affiliation: University of Texas Southwestern Medical Center, , Dallas, TX 75390-9133, USA.
authors.forename: Christopher
authors.initials: C
authors.lastname: Straka
authors.forename: D W Nathan
authors.initials: DW
authors.lastname: Kim
authors.forename: Robert D
authors.initials: RD
authors.lastname: Timmerman
authors.forename: Ivan
authors.initials: I
authors.lastname: Pedrosa
authors.forename: Corbin
authors.initials: C
authors.lastname: Jacobs
authors.forename: James
authors.initials: J
authors.lastname: Brugarolas
mesh_terms: D055011:Ablation Techniques; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000601:surgery*; D003131:Combined Modality Therapy; D018450:Disease Progression; D004334:Drug Administration Schedule; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D008297:Male; D011758:Pyrroles / Q000008:administration & dosage*; D016634:Radiosurgery / Q000379:methods; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib